[
  {
    "ts": "2025-12-10T09:30:00+00:00",
    "headline": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
    "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
    "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
    "source": "South China Morning Post",
    "provider": "yfinance",
    "raw": {
      "id": "e5809500-2c36-38a7-8c06-27c432a47945",
      "content": {
        "id": "e5809500-2c36-38a7-8c06-27c432a47945",
        "contentType": "STORY",
        "title": "China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer",
        "description": "",
        "summary": "US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050",
        "pubDate": "2025-12-10T09:30:00Z",
        "displayTime": "2025-12-10T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c",
          "originalWidth": 1999,
          "originalHeight": 1445,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NrMYkjybZfgvsVPgy08KfA--~B/aD0xNDQ1O3c9MTk5OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 1999,
              "height": 1445,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vF.Bc5MyIqpbyFQCk.k5zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/south_china_morning_post_us_228/5c8f5f94b861b28d927dd2d23d8a774c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "South China Morning Post",
          "url": "https://www.scmp.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chinas-fosun-pharma-unit-strikes-093000723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]